home / stock / sls / sls news


SLS News and Press, SELLAS Life Sciences Group Inc.

Stock Information

Company Name: SELLAS Life Sciences Group Inc.
Stock Symbol: SLS
Market: NASDAQ
Website: sellaslifesciences.com

Menu

SLS SLS Quote SLS Short SLS News SLS Articles SLS Message Board
Get SLS Alerts

News, Short Squeeze, Breakout and More Instantly...

SLS - SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe - - SELLAS’ Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized - - Topline Data Expected in Q4 2026 – NEW YORK, March 12, 2026 (GLOBE ...

SLS - Sellas Life Sciences: REGAL Study Results Due Any Day Are A Major Potential Upside Catalyst

2026-03-05 12:01:40 ET Investment Overview New York headquartered Sellas Life Sciences ( SLS ) listed on the Nasdaq in August 2017 via a merger with struggling biotech Galena Biopharma - a press release at the time stated: SELLAS’ lead asset, galinpepimut-S ...

SLS - Why I'm Selling Sellas Life Sciences Ahead Of The REGAL Reveal

2026-01-19 08:07:13 ET Sellas Life Sciences’ stock ( SLS ) has risen >300% in the past year ahead of Phase 3 data for its peptide immunotherapy, galinpepimut-S (GPS), in patients with AML in second remission.... Read the full article on Seeking Alpha For furthe...

SLS - SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment  U.S. enrollment evaluating SLS009 in combination with AZA/VEN in newly diagnosed AML with high-risk features is planned for Q1 2026, with European...

SLS - The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Biopharma M&A is entering a fever pitch, with precision oncology investments alone exploding to $138 billion as major players scramb...

SLS - US Companies Moving the Markets, Evening edition
Tue, Jan 06, 2026 as of 4:00 pm ET

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 9.2% to $2.3963 on volume of 453,152,238 shares Envirotech Vehicles Inc. (EVTV) rose 55.6% to $0.6 on volume of 374,606,573 shares Oriental Culture Holding LTD (OCG) fell 41.5% to ...

SLS - Catalyst Watch: AI spotlight at CES, Versant starts trading, and the December jobs report

2026-01-02 15:00:31 ET More on the markets Realistic Expectations For 2026 Market Rotation Alert: Positioning For A Potentially Tumultuous Year S&P 500 And Bitcoin: After 4 Years Of Mediocrity From The Latter, I Own Both, Here's Why Steady start to 2026: ...

SLS - Top 5 Small-cap Biotech Stocks of 2025

2025-12-30 14:10:00 ET The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to breakthrough innovations and increased deals involving NASDAQ biotech stocks. After dropping to a low of 3,637.05 in October 2023, the ...

SLS - SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomes Timing of the final analysis is event-driven, and SELLAS will announce the occurrence of the 80 th event...

SLS - Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034 [1] , driven by a fundamental shift in how physicians combat cancer's most resistant forms. ...

Next 10